ReNeuron Group (LON:RENE) issued its quarterly earnings data on Thursday. The company reported GBX (45.20) (($0.59)) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of GBX (49.80) (($0.65)) by GBX 4.60 ($0.06), Bloomberg Earnings reports.
Shares of RENE stock opened at GBX 237.50 ($3.10) on Friday. The stock’s fifty day moving average is GBX 250.07. ReNeuron Group has a 12-month low of GBX 29.50 ($0.39) and a 12-month high of GBX 342 ($4.47). The company has a market capitalization of $75.53 million and a P/E ratio of -5.61.
In related news, insider Christopher Evans acquired 10,000 shares of the stock in a transaction dated Thursday, April 18th. The stock was bought at an average price of GBX 229 ($2.99) per share, with a total value of £22,900 ($29,922.91).
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
Further Reading: Buy Rating
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.